These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

495 related articles for article (PubMed ID: 34693730)

  • 1. Feature Selection is Critical for 2-Year Prognosis in Advanced Stage High Grade Serous Ovarian Cancer by Using Machine Learning.
    Laios A; Katsenou A; Tan YS; Johnson R; Otify M; Kaufmann A; Munot S; Thangavelu A; Hutson R; Broadhead T; Theophilou G; Nugent D; De Jong D
    Cancer Control; 2021; 28():10732748211044678. PubMed ID: 34693730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integration of histopathological images and multi-dimensional omics analyses predicts molecular features and prognosis in high-grade serous ovarian cancer.
    Zeng H; Chen L; Zhang M; Luo Y; Ma X
    Gynecol Oncol; 2021 Oct; 163(1):171-180. PubMed ID: 34275655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deep learning provides a new computed tomography-based prognostic biomarker for recurrence prediction in high-grade serous ovarian cancer.
    Wang S; Liu Z; Rong Y; Zhou B; Bai Y; Wei W; Wei W; Wang M; Guo Y; Tian J
    Radiother Oncol; 2019 Mar; 132():171-177. PubMed ID: 30392780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of Artificial Intelligence for Preoperative Diagnostic and Prognostic Prediction in Epithelial Ovarian Cancer Based on Blood Biomarkers.
    Kawakami E; Tabata J; Yanaihara N; Ishikawa T; Koseki K; Iida Y; Saito M; Komazaki H; Shapiro JS; Goto C; Akiyama Y; Saito R; Saito M; Takano H; Yamada K; Okamoto A
    Clin Cancer Res; 2019 May; 25(10):3006-3015. PubMed ID: 30979733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Machine learning algorithms for outcome prediction in (chemo)radiotherapy: An empirical comparison of classifiers.
    Deist TM; Dankers FJWM; Valdes G; Wijsman R; Hsu IC; Oberije C; Lustberg T; van Soest J; Hoebers F; Jochems A; El Naqa I; Wee L; Morin O; Raleigh DR; Bots W; Kaanders JH; Belderbos J; Kwint M; Solberg T; Monshouwer R; Bussink J; Dekker A; Lambin P
    Med Phys; 2018 Jul; 45(7):3449-3459. PubMed ID: 29763967
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The molecular prognostic score, a classifier for risk stratification of high-grade serous ovarian cancer.
    Sarkar S; Saha SA; Swarnakar A; Chakrabarty A; Dey A; Sarkar P; Banerjee S; Mitra P
    J Ovarian Res; 2024 Aug; 17(1):159. PubMed ID: 39095849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models.
    Jalali-Najafabadi F; Stadler M; Dand N; Jadon D; Soomro M; Ho P; Marzo-Ortega H; Helliwell P; Korendowych E; Simpson MA; Packham J; Smith CH; Barker JN; McHugh N; Warren RB; Barton A; Bowes J; ;
    Sci Rep; 2021 Dec; 11(1):23335. PubMed ID: 34857774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-Grade Serous Ovarian Cancer: Use of Machine Learning to Predict Abdominopelvic Recurrence on CT on the Basis of Serial Cancer Antigen 125 Levels.
    Shinagare AB; Balthazar P; Ip IK; Lacson R; Liu J; Ramaiya N; Khorasani R
    J Am Coll Radiol; 2018 Aug; 15(8):1133-1138. PubMed ID: 29789232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
    Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cox-LASSO Analysis Reveals a Ten-lncRNA Signature to Predict Outcomes in Patients with High-Grade Serous Ovarian Cancer.
    Xu L; Wu Y; Che X; Zhao J; Wang F; Wang P; Qu X; Liu Y; Li Z
    DNA Cell Biol; 2019 Dec; 38(12):1519-1528. PubMed ID: 31657627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Machine Learning analysis of high-grade serous ovarian cancer proteomic dataset reveals novel candidate biomarkers.
    Farinella F; Merone M; Bacco L; Capirchio A; Ciccozzi M; Caligiore D
    Sci Rep; 2022 Feb; 12(1):3041. PubMed ID: 35197484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical factors associated with prognosis in low-grade serous ovarian carcinoma: experiences at two large academic institutions in Korea and Taiwan.
    Kang JH; Lai YL; Cheng WF; Kim HS; Kuo KT; Chen YL; Lee YY
    Sci Rep; 2020 Nov; 10(1):20012. PubMed ID: 33203969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraoperative Diagnosis Support Tool for Serous Ovarian Tumors Based on Microarray Data Using Multicategory Machine Learning.
    Park JS; Choi SB; Kim HJ; Cho NH; Kim SW; Kim YT; Nam EJ; Chung JW; Kim DW
    Int J Gynecol Cancer; 2016 Jan; 26(1):104-13. PubMed ID: 26512784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies.
    Wu Q; Tian R; He X; Liu J; Ou C; Li Y; Fu X
    Front Immunol; 2023; 14():1164408. PubMed ID: 37090728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Candidate prognostic biomarkers and prediction models for high-grade serous ovarian cancer from urinary proteomics.
    Ni M; Wan D; Wu J; Gong W; Wang J; Zheng Z
    J Proteomics; 2024 Jul; 304():105234. PubMed ID: 38925351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing prognostic factors of five-year survival in gastric cancer patients using feature selection techniques with machine learning algorithms: a comparative study.
    Afrash MR; Mirbagheri E; Mashoufi M; Kazemi-Arpanahi H
    BMC Med Inform Decis Mak; 2023 Apr; 23(1):54. PubMed ID: 37024885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New immune phenotypes for treatment response in high-grade serous ovarian carcinoma patients.
    Torkildsen CF; Austdal M; Jarmund AH; Kleinmanns K; Lamark EK; Nilsen EB; Stefansson I; Sande RK; Iversen AC; Thomsen LCV; Bjørge L
    Front Immunol; 2024; 15():1394497. PubMed ID: 38947323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
    Javellana M; Hoppenot C; Lengyel E
    Gynecol Oncol; 2019 Feb; 152(2):228-234. PubMed ID: 30471899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.